Rapamycin combined with osimertinib alleviated non-small cell lung cancer by regulating the PARP, Akt/mTOR, and MAPK/ERK signaling pathways
In conclusion, the study demonstrated that Rapamycin combined with Osimertinib can inhibit the cell migration, regulate the cell cycle, promote the autophagy and apoptosis, increase the ROS level and regulate the PARP, MAPK/EKR, and Akt/mTOR pathways in A549 and PC-9 cells, providing a novel theoretical basis for their clinical treatment of NSCLC.
Authors
- Haiping Xiao
- Kai Chen (ORCID: https://orcid.org/0000-0002-8647-1182)
- Qingping Ma (ORCID: https://orcid.org/0000-0003-4196-1484)
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2025-03-07
- DOI
- https://doi.org/10.3389/fmolb.2025.1548810
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56